Form 4: Evoke Pharma Director Kenneth J. Widder Reports Stock Option Grant

Director Kenneth J. Widder reports the acquisition of stock options in Evoke Pharma, Inc.

Summary

• Kenneth J. Widder, a director of Evoke Pharma Inc, filed a Form 4 on January 29, 2025, reporting a transaction.
• On January 28, 2025, Widder acquired stock options for 5,833 shares of Evoke Pharma's common stock at an exercise price of $4.45.
• The options vest in three equal annual installments starting from the vesting commencement date, contingent upon continued service to the company.
• Following the reported transaction, Widder directly owns options for 5,833 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It simply reports the grant of stock options.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to monitor the actions of those with privileged information.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, stock options, Evoke Pharma, director, beneficial ownership, securities